We describe a "high performance" liquid chromatographic method for quantitating methyiphenidate in serum. The internal standard, 4,5-diphenylimidazole, and a serum or plasma sample are extracted in chloroform, evaporated, and redissolved in 20 mmol/L potassium phosphate (pH 3.5)/high-purity acetonitrile, 80/20 by vol. A centrifuged aliquot is chromatographed on t-Bondapak C-i 8 with the phosphate/acetonitrile solvent as mobile phase, a flow rate of 1.6 mL/min, and a column temperature of 40 #{176}C. Absorbances are read at 192 nm. This method reliably measures concentrations >20 tg/L and has analytical recoveries of 74%. 
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Methylphenidate
[methyl a-phenyl-a-(2-piperidyl)acetate, (ritalin)1 has pharmacological properties similar to those of dextroamphetamine (1) and has been used to treat children with hyperkinesis (2) as well as patients with depression. According to recent estimates from the United States, 1-2% of the children labeled as hyperactive are currently receiving this medication (3) . Following oral administration of methylphenidate, about 75% of the original dose is recovered as ritalinic acid [a-phenyl-a-(2-piperidyl)acetic acid] in urine (4,5) (see Figure 1 ). Minor metabolic pathways for both these compounds include parahydroxylation of the aromatic ring, oxidation to the 6-oxo-derivatives, and glucuronide formation (5) (6) (7) (8) (9) (10) (11) .
Gas-chromatographic and gas-chromatographic-massspectrometric procedures recently described for quantitation of methylphenidate and ritalinic acid (11) (12) (13) (14) require relatively large sample volumes (2-5 mL of plasma or serum). Because the hyperactive syndrome is a childhood disorder, a microprocedure foranalysisof both these compounds would be a distinct improvement over current methodologies. We have recently described a reliable microprocedure for the analysis for ritalinic acid in serum (15) , and we now present a rapid, reliable, and sensitive "high performance" liquid chromatographic procedure for the analysis for methylphenidatein serum.
Materials and Methods
Apparatus
Throughout these studies, we used a "high performance" Table 1 .
Results and Discussion
Analytical Variables
Detector wavelength. Figure 2 shows an absorbance scan for methylphenidate and 4,5-diphenylimidazole. Clearly, monitoring the absorbance at 192 nm will give a more sensitive assay for methylphenidate than will a higher wavelength. The between-day precision of the method (n = 20) was assessed by the repeated analyses of serum specimens containing various concentrations of methyiphenidate. At concentrations of 135, 252, and 497 MgfL, the method yielded coefficients of variation of 12.2, 7.5, and 9.4%, respectively. Sensitivity.
The minimum detection limit is based on the peak height relative to the baseline noise (16) and on the re- producibility of that peak height for a serum sample with a given concentration of methylphenidate.
In the analysis for linearity a signal-to-baseline-noise ratio of 2 corresponds to a minimum detection limit of 10 g/L. This, together with the precision data, suggests that methylphenidate cannot be reliably estimated by our procedure at concentrations of less than 20 Mg/L. Recovery.
We measured absolute recovery from plasma of methylphenidate and 4,5-diphenylimidazole as follows. To three different samples of drug-free plasma we added the two compounds to the concentrations shown in Table 2 . We performed the analysis as described, except that the 3.0 mL of chloroform added to the 300 ML of serum contained no 4,5-diphenylimidazole.
We carefully measured and chromatographed aliquots of the final solutions and determined the peak heights.
We calculated percentage recovery by comparing these peak heights with the peak heights obtained by direct injection of the pure compounds.
As shown in of methyiphenidate and ritalinic acid in a 12-year-old boy.
From this graph we calculated the half-life for methylphenidate and ritalinic acid to be 2.6 and 3.2 h, respectively. Correlations between psychological performance and serum concentrations of both methylphenidate and its major metabolite ritalinic acid are currently being undertaken. The availability of procedures for the analysis of these compounds will enable us to assess whether the therapeutic effect of methylihenidate is due to the parent drug, its major metabolite, or both, by correlating psychological performance (17) with serum concentration of these compounds. The relationship between drug dose and the concentration of parent drug and its metabolites in serum is unpredictable because of inter-individual differences in drug absorption, metabolism, and excretion. Correlation of concentrations in serum with behavioral response would eliminate the semiempiricism of current practice and make possible more rational diagnosis and management.
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